Cargando…
Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641992/ http://dx.doi.org/10.1186/1750-1172-10-S1-O21 |
| _version_ | 1782400281509625856 |
|---|---|
| author | Gillmore, Julian D Falk, Rodney H Maurer, Mathew S Hanna, Mazen Karsten, Verena Vest, John Gollob, Jared Hawkins, Philip N |
| author_facet | Gillmore, Julian D Falk, Rodney H Maurer, Mathew S Hanna, Mazen Karsten, Verena Vest, John Gollob, Jared Hawkins, Philip N |
| author_sort | Gillmore, Julian D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4641992 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46419922015-11-19 Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis Gillmore, Julian D Falk, Rodney H Maurer, Mathew S Hanna, Mazen Karsten, Verena Vest, John Gollob, Jared Hawkins, Philip N Orphanet J Rare Dis Oral Presentation BioMed Central 2015-11-02 /pmc/articles/PMC4641992/ http://dx.doi.org/10.1186/1750-1172-10-S1-O21 Text en Copyright © 2015 Gillmore et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Gillmore, Julian D Falk, Rodney H Maurer, Mathew S Hanna, Mazen Karsten, Verena Vest, John Gollob, Jared Hawkins, Philip N Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| title | Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| title_full | Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| title_fullStr | Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| title_full_unstemmed | Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| title_short | Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| title_sort | phase 2, open-label extension (ole) study of revusiran, an investigational rnai therapeutic for the treatment of patients with transthyretin cardiac amyloidosis |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641992/ http://dx.doi.org/10.1186/1750-1172-10-S1-O21 |
| work_keys_str_mv | AT gillmorejuliand phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT falkrodneyh phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT maurermathews phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT hannamazen phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT karstenverena phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT vestjohn phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT gollobjared phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis AT hawkinsphilipn phase2openlabelextensionolestudyofrevusirananinvestigationalrnaitherapeuticforthetreatmentofpatientswithtransthyretincardiacamyloidosis |